metaPreg - Tacrolimus (all routes) during pregnancy

Tacrolimus (all routes) updated on 03-16-2022

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	0.46 [0.07, 3.05]	0%	2 studies	4	30	not evaluable	ROB	-
1 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	0.99 [0.36, 2.69]	39%	4 studies	50	82	not evaluable	ROB	-
Low birth weight (< 2500g)	2.02 [0.86, 4.75]	0%	2 studies	27	43	not evaluable	ROB	-
Small for gestational age (weight)	0.87 [0.12, 6.18]	0%	2 studies	12	13	not evaluable	ROB	-
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preeclampsia	2.26 [0.63, 8.11]	0%	4 studies	19	49	not evaluable	ROB	-
Caesarean	1.34 [0.73, 2.48]	0%	3 studies	92	70	not evaluable	ROB	-
2 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
1 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Late intrauterine deaths (> 22 weeks) / Stillbirths	0.95 [0.04, 20.57]	46%	2 studies	3	42	not evaluable	ROB	-
1 non statistically significant endpoints reported in only one study